Eosinophil Indices in Patients With Acute Heart Failure

Status Completed

Clinical Trial Summary

All consecutive patients admitted to the intensive care unit (ICU) with ADHF between January 2017 and December 2021 were enrolled in this retrospective study. All-cause mortality and MACE were assessed with respect to relationships with eosinophil indices, including neutrophil-to-eosinophil ratio (NER), leukocyte-to-eosinophil ratio (LER), eosinophil-to-lymphocyte ratio (ELR), and eosinophil-to-monocyte ratio (EMR).

Clinical Trial Description

All consecutive patients admitted to the intensive care unit (ICU) with ADHF and reduced EF between January 2017 and December 2021 were enrolled in this retrospective study. HFrEF was defined as having an LVEF of ≤40%. Demographic data were retrieved from patient charts and the institutional digital database. Patients with an LVEF >40%, NYHA Class I and II subjects, those with advanced liver, kidney diseases or malignancies, patients in whom life expectancy was extremely short and patients with autoimmune, allergic, or infectious diseases that affect the eosinophil indices were not included in the study. The study was approved by the local ethics committee. Conventional guidelines had been followed for the in-hospital treatment of all patients with ADHF, including loop diuretics, vasodilators, inotropes/vasopressors [9]. Blood tests including complete blood count, blood urea nitrogen and creatinine, electrolytes, liver enzymes, and NT-pro BNP were ordered upon admission to the ICU. All patients underwent transthoracic echocardiography. LVEF was measured with 2-dimensional echocardiography via the modified Simpson method [10]. Data concerning 6-month all-cause mortality and MACE were retrieved from the institutional digital database. The definition of MACE was the composite of total death and re-hospitalization for HF within 6 months of initial hospitalization. The primary outcome measure of this study was all-cause mortality within the first 6 months of index hospitalization and its relationship with eosinophil indices, including NER, LER, ELR and EMR. The secondary outcome measure of this study was the assessment of MACE within the first 6 months of index hospitalization and its association with eosinophil indices. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05410990
Study type	Observational [Patient Registry]
Source	Giresun University
Contact
Status	Completed
Phase
Start date	January 2, 2017
Completion date	April 5, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02151383` - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure	Phase 2
Completed	`NCT02135835` - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure	Phase 4
Recruiting	`NCT05556044` - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction	Phase 3
Recruiting	`NCT04363697` - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)	Phase 4
Completed	`NCT02122640` - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department	N/A
Not yet recruiting	`NCT01211886` - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)	N/A
Completed	`NCT01193998` - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department	N/A
Recruiting	`NCT05276219` - Optimized Treatment of Pulmonary Edema or Congestion	Phase 4
Recruiting	`NCT05392764` - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	Phase 3
Recruiting	`NCT03157219` - Manipal Heart Failure Registry (MHFR)	N/A
Completed	`NCT06024889` - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.	Phase 1/Phase 2
Terminated	`NCT04174794` - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting	`NCT05972746` - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure	N/A
Enrolling by invitation	`NCT02258984` - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial	N/A
Completed	`NCT02141607` - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed	`NCT01870778` - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF	Phase 3
Recruiting	`NCT05986773` - Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance	Phase 4
Recruiting	`NCT04163588` - Sequential Nephron Blockade in Acute Heart Failure	Phase 3
Recruiting	`NCT04329234` - Korean Heart Failure Registry III
Recruiting	`NCT03720288` - Acetazolamide in Patients With Acute Heart Failure	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.